Dr. Hillel Grossman is Co-Director of the Clinical Research Core of the Alzheimer's Disease Research Center and Clinical Director of the Mount Sinai Memory and Aging Center. Dr. Grossman is a psychiatrist by training with a focus in geriatric neuropsychiatry and has been involved in designing and conducting clinical studies in Alzheimer's disease. His studies are both observational, e.g. what happens as Alzheimer's progresses and interventional e.g. clinical trials. At present he is the Principal Investigator or Co-Principal investigator on numerous studies of potential treatments or diagnostic tools for Alzheimer's disease. Dr. Grossman has received funding from the NIH, VA and foundations for his investigations of interaction between Alzheimer's and Type II diabetes mellitus and the potential use of a natural insulin sensitizer, NIC5-15, in Alzheimer's disease. Dr. Grossman has also conducted work in the relationship late life depression and cognitive performance in HIV-1 infection.
Psychiatry, American Board of Psychiatry and Neurology
MD, University of Tennessee
Johns Hopkins Hospital
Fellowship, Geriatric Neuropsych
Univeristy of Rochester
The Study of Nasal Insulin to Fight Forgetfulness
Volunteers are being recruited for the SNIFF study. This study is investigating the safety tolerability and effectiveness of an insulin nasal spray when given to people with Alzheimer's disease (AD) or mild cognitive impairment. Insulin is a hormone in your body that helps your c...
Alzheimer’s Disease Neuroimaging Initiative-2 (ADNI-2)
In this study, we hope to determine whether imaging of the brain through MRI, PET, and amyloid imaging scans can help predict and monitor the onset and progression of Alzheimer's disease. In addition to neuroimaging, the study will collect and test blood and cerebral spinal fluid...
Silverman JM, Beeri MS, Grossman HT, Schmeidler J, Wang JY, Lally RC. A phenotype for genetic studies of successful cognitive aging. Neuropsychiatric Genetics;: in press.
Sano M, Grossman HT, Van Dyk K. Preventative strategies against Alzheimer's disease: separating fact from fiction. CNS Drugs;: in press.
Beeri MS, Rapp M, Schmeidler J, Reichenberg A, Purohit DP, Perl DP, Grossman HT, Prohovnik I, Haroutunian V, Silverman JM. Number of children is associated with neuropathology of Alzheimer's disease in women [ahead of print]. Neurobiology of Aging;.
Beeri MS, Silverman JM, Sano M, Wang J, Lally R, Grossman HT, Schmeidler J. Age, gender and education norms on the CERAD neuropsychological battery in the oldest old. Neurology 2006 Sep 26; 67(6): 1006-1010.
Grossman HT, Bergmann C, Parker S. Dementia: a brief review. Mount Sinai Journal of Medicine 2006 November; 73(7): 985-992.
Beeri MS, Silverman JM, Uribarri J, Grossman HT, Rosendorff C, Langhoff E, Lally R, Wang J, Schmeidler J. Normal homocysteine levels in well functioning oldest old individuals despite low kidney function. Journal of the American Geriatrics Society(JAGS) 2006 Oct; 54(10): 1623.
Beeri MS, Rapp MA, Silverman JM, Schmeidler J, Grossman HT, Perl DP, Purohit DP, Fallon JT, Siddiqui A, Lesser G, Rosendorff C, Haroutunian VH. Coronary Artery Disease is Associated with Alzheimer's Disease Neuropathology in APOE4 carriers. Neurology 2006 May 9; 66(9): 1399-1404.
Rapp MA, Beeri MS, Grossman HT, Sano M, Perl DP, Gorman JM, Haroutunian VH. Increased hippocampal plaques and tangles in patients with Alzheimer disease with a lifetime history of major depression. Arch Gen Psychiatry 2006 Feb; 63(2): 161-167.
Beeri MS, Silverman JM, Davis KL, Marin DB, Grossman HT, Schmeidler J, Purohit DP, Perl DP, Davidson M, Mohs RC, Haroutunian V. Type II Diabetes is Negatively Associated with Alzheimer's Disease Neuropathology. J Gerontol A Biol Sci Med Sci 2005 Apr; 60(4): 471-475.
Rapp MA, Dahlman K, Sano M, Grossman HT, Haroutunian V, Gorman JM. Neuropsychological Differences between Late-Onset and Recurrent Geriatric Major Depression. American Journal of Psychiatry 2005 Apr; 162(4): 691-698.
Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device and biotechnology companies to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their relationships with such companies.
Dr.Grossman did not report having any of the following types of financial relationships with industry during 2015 and/or 2016: consulting, scientific advisory board, industry-sponsored lectures, service on Board of Directors, participation on industry-sponsored committees, equity ownership valued at greater than 5% of a publicly traded company or any value in a privately held company. Please note that this information may differ from information posted on corporate sites due to timing or classification differences.
Mount Sinai's faculty policies relating to faculty collaboration with industry are posted on our website. Patients may wish to ask their physician about the activities they perform for companies.
Physicians who provide services at hospitals and facilities in the Mount Sinai Health System might not participate in the same health plans as those Mount Sinai hospitals and facilities (even if the physicians are employed or contracted by those hospitals or facilities).
Information regarding insurance participation and billing by this physician may be found on this page, and can also be obtained by contacting this provider directly. Because physicians insurance participation can change, the insurance information on this page may not always be up-to-date. Please contact this physician directly to obtain the most up-to-date insurance information.
Insurance and health plan networks that the various Mount Sinai Health System hospitals and facilities participate in can be found on the Mount Sinai Health System website.